Advanced Biomarker Detection for Pharmacological Monitoring in the Brain
The objective of the research group is to develop an in vivo continuous monitoring biosensor for the direct detection of small molecule biomarkers in brain tissue of rodent models for elucidating the pharmacodynamic (PD) effect and pharmacokinetic (PK) parameters of drugs against neuropsychiatric diseases. The team will explore the multifaceted task of continuous monitoring biosensor development, including molecular design and assay development, biocompatible sensor architecture, and sensor integration for in vivo monitoring.
Mentors
Dr. Roberto Arban (Industry mentor) Director Neuroscience & Mental Health Discovery Research at Boehringer Ingelheim Pharma GmbH & Co. KG., Germany
Prof. Dr. Heather A. Clark (Academic mentor) Director, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, USA
Dr. Jakub Dostálek (Academic mentor)
Head of Laboratory, Institute of Physics of the Czech Academy of Sciences
Prague, Czech Republic
Publications
Cátia Santa, Soohyun Park, Artur Gejt, Heather A. Clark, Bastian Hengerer and Khulan Sergelen (2025). Real-time monitoring of vancomycin using a split-aptamer surface plasmon resonance biosensor Analyst
Soohyun Park, Alice Gerber, Cátia Santa, Gizem Aktug, Bastian Hengerer, Heather A. Clark, Ulrich Jonas, Jakub Dostalek, Khulan Sergelen (2025). Molecularly Responsive Aptamer-Functionalized Hydrogel for Continuous Plasmonic Biomonitoring JACS
The research of this team is kindly supported by Boehringer Ingelheim.
Our Team Members
Dr. Khulan Sergelen
Group Leader
Short Bio
2019 – 2022: Assistant Professor (tenure-track), Eindhoven University of Technology, Netherlands
2018 – 2019: Postdoctoral researcher at Molecular Biosensing for Medical Diagnostics (MBx) group, Eindhoven University of Technology, Netherlands
Continuous monitoring biosensors based on particle mobility for inflammatory biomarkers monitoring application
2012 – 2017: PhD joint degree in Bionanotechnology (IGS-BioNanoTech) at the University of Natural Resources and Life Sciences (BOKU), Vienna and Nanyang Technological University (NTU), Singapore
Reversible biosensors using aptamer-based surface plasmon-enhanced fluorescence spectroscopy and hydrogel architectures towards therapeutic drug monitoring application
2009 – 2012: MSc Molecular Medicine, University of Vienna, Austria
Protein microarray screening of tumor autoantibodies for early colon cancer detection- Austrian Institute of Technology, Vienna
At BioMed X we care for the people who work with us. Staying in touch with those who left but mainly contributed to BioMed X’s success is key. That’s why they have their designated place on our website. So let’s keep connected!
Schizophrenia as being a neurodevelopmental disorder, shows aberrations not only in structure, wiring and chemistry of multiple neuronal systems but also in myelination. The team is interested in deciphering the causes of this so far untapped pathology occurring due to myelination deficits.
The project’s cores are to develop a ligand specific for a target cell and establish quantitative assessment methods to monitor macromolecular drug delivery across the intestinal epithelial barrier.